# An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

Source: https://onco.cc/trials/nct02955940/  
OnCo record `nct02955940` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Ruxolitinib, Capecitabine, Regorafenib in colorectal cancer, run by Incyte Corporation, active and no longer recruiting.

## Summary

An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib is a phase 2 interventional study registered as NCT02955940 by Incyte Corporation, with 10 participants enrolled, started 2016-11-30 and due to reach its primary completion in 2027-09-30. Interventions recorded: Ruxolitinib, Capecitabine, Regorafenib. Conditions listed: Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer, Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT02955940
- Phase: 2
- Setting: An Open-Label, Multicenter, Rollover Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
- Sponsor: Incyte Corporation
- Enrolled: 10

## Sources

- ClinicalTrials.gov NCT02955940: https://clinicaltrials.gov/study/NCT02955940

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Regorafenib](https://onco.cc/drugs/regorafenib/), [Ruxolitinib](https://onco.cc/drugs/ruxolitinib/)
- companies: [Incyte](https://onco.cc/companies/incyte/)

---
JSON: https://onco.cc/api/v1/entities/nct02955940.json